AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 293 min read$INSM

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 6:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Insmed (INSM) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$INSMBullishHigh
01

Why it matters

The guidance increase signals higher future cash flow, likely supporting the stock price.

02

Market read

Earnings guidance lift is a material catalyst for INSM and may influence peer valuations.

03

What to watch

Potential regulatory or reimbursement hurdles in Japan could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Insmed's Q3 2026 earnings call highlighted strong sales of BRINSUPRI and raised full‑year guidance.

Company-level read

Ticker impact

$INSMBullishHigh confidence
Context

Insmed raised its full-year 2026 revenue guidance to $1.35‑$1.4 B, up $100 M at the low end, and reported $400.1 M Q3 revenue for BRINSUPRI.

Expected impact

likely upward pressure as investors price in higher revenue expectations

Evidence & confidence

The new guidance is a primary disclosure with material scale, indicating improved earnings outlook.

Market effects

Sector

Boosts outlook for the respiratory biotech sector as a benchmark for product launches.

Regional

Positive for US biotech equities, modest effect on Asian markets where the product launched.

Global

Limited to investors tracking biotech earnings and pipeline updates.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock may face a short‑term pullback.

Key entities

  • company
    Insmed

    US‑listed biotech focused on respiratory therapies.

Read at source← All news

StoryInsmed raises 2026 revenue guidance after strong third-quarter results

Also covered by

4 outlets

Related articles

OCT 30
$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

finance.yahoo.com2 min
OCT 30
$INSMHighAI 9/10

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

investing.com2 min
OCT 29
$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

finance.yahoo.com2 min
OCT 29
$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

finance.yahoo.com2 min
OCT 29
HighAI 8/10

Insmed surges on Q3 revenue beats, revenue guidance range raise

Insmed's stock rose 13% after Q3 results beat revenue estimates. The company raised full-year revenue guidance for Brinsupri and Arikayce. Q3 GAAP EPS was -$0.46, an improvement from -$1.75 last year. Brinsupri revenue grew 29% QoQ, while Arikayce revenue increased 9%. Cash reserves were ~$1.15B at Q3's end.

tradingview.com1 min